Predicting the future of EU genetic testing regulation - opportunities and pitfalls
This article was originally published in Clinica
Executive Summary
How should genetic tests be regulated in the EU? What special provisions should there be given the potential far-reaching impact of a patient learning they have an incurable disease, for example? Should they be freely available on the Internet, and how can users be protected from advertising? Joanna Hook and Grant Strachan, associates in the regulatory department of law firm Bristows LLP, look at the current regulation of these tests and at how the EU is likely to become much more challenging for manufacturers with the future revision of its IVD requirements
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.